Dissecting the cellular architecture of breast cancer brain metastases reveals prognostically distinct immune landscapes dlvr.it/TSz5Qh

Excited to hear María Casanova Acebes @Casanova_Acebes present her talk "Decoding time: Circadian and longitudinal myeloid landscapes in lung cancer" @CellPressEvents #CSHallmarks2026 Submit an abstract for a chance to join her: hubs.li/Q04l2dn50

Don't miss @UCSanDiego Theodore Alexandrov's talk "High-throughput spatial single-cell metabolomics: decoding metabolism one cell at a time" @CellPressEvents #CSHallmarks2026 in Sitges, Spain, Nov 1–3, 2026. Submit an abstract before June 26: hubs.li/Q04k93tp0)

A holy grail for our lab has been tracking myeloid cells in human tumors in the same way that we track T and B cells with TCR/BCR. @vincentzliu and @CalebLareau solved it! We developed Mitotrek using scATAC-seq mitochondrial DNA to do exactly this. Using Mitotrek, we find that new myeloid cells clones constantly infiltrate the tumor via circulating monocytes — and that their macrophage or dendritic cell fate is epigenetically programmed before tumor entry. @10xGenomics @parkerici @CancerResearch @TheMarkFdn cell.com/cancer-cell/fulltex…

Can ctDNA transform the management of biliary tract cancers? Our new @trendscancer forum paper outlines the promise, limitations, and path toward clinical implementation. Grateful to all collaborators who made this work possible. @PrecisionBTCnet @atuvibi cell.com/trends/cancer/abstr…

Online Now: Endocytic evasion confers resistance to antibody-drug conjugates therapy in cancer dlvr.it/TSghCJ

Be part of the Hallmarks of cancer legacy. Join our distinguished keynote speakers Johanna Joyce @Joycelab & Faisal Mahmood @AI4Pathology in Sitges, Spain, November 1–3, 2026. Abstract deadline: June 26, 2026 🔗hubs.li/Q04h4PzV0 @CellPressEvents #CSHallmarks2026

Interested in #DNAmethylation predictors of #cancer response to #immune checkpoint inhibitors, #targetedtherapy, and #chemotherapy? 🔎 Our recent Trends in Cancer @TrendsCancer @CellPressNews article summarizes the field : Don’t miss Table 1 for a comprehensive list! sciencedirect.com/science/ar…

🚨 Out today in Cell! @CellCellPress Path2Space: #AI that predicts spatial transcriptomics (ST) from H&E pathology, enabling spatial biomarker discovery in #BreastCancer at scale. 📄 doi.org/10.1016/j.cell.2026.… 🧵1/8

🧬 #ScienceSaturday ❓ What if cancer treatment could target not only tumor cells, but also the tumor’s stromal support: non-malignant, non-cancerous cells within the tumor microenvironment, that actively help cancer grow, spread, and resist treatment? ➡️ In a new study published in @CellCellPress, researchers identified uPAR, a cell-surface protein linked to aggressive tumor behavior, as a marker found on both solid tumor cells and the fibrotic, immune-suppressive environment that helps sustain them. ➡️ The team developed uPAR-targeted CAR T cells that attacked both tumor cells and their supportive stroma, leading to durable tumor regression across multiple cancer models, including metastatic disease. ➡️ They also found that senescence-inducing therapies, like chemotherapy, increased uPAR expression and made tumors even more vulnerable to CAR T cell treatment. 🌟 This dual-targeting strategy could help overcome some of the biggest barriers to CAR T therapy in solid tumors, including immune suppression and treatment resistance. 🔗 Read the study: cell.com/cell/fulltext/S0092… @ZedaZhang @Aveline_Filliol @LoweLabMSKCC

See what the organizers have to say about @CellPressEvents #CSHallmarks2026 and join them in Spain, Nov 1–3, 2026, to celebrate the convergence of basic and translational science, spark new connections, and shape the future of precision oncology. hubs.li/Q04fDr7q0

Daraxonrasib in Previously Treated Advanced RAS-Mutated #PancreaticCancer (Phase 1-2 study) nejm.org/doi/pdf/10.1056/NEJ… @RevMedicines @salmanpunekar

Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer @jclinicalinvest @DrIgMelero @ClinicaNavarra @CIMA_unav jci.org/articles/view/200987 🇪🇸

New @Cancer_Cell paper on mechanisms of resistance to @RevMedicines Daraxonrasib Disrupted molecular glue complex drives RAS inhibitor resistance cell.com/cell/fulltext/S0092… 18/40 genomic alterations in RAS pathway (👇🏽) Recurrent RAS Y64 alteration attenuates tri-complex formation

1/ Thrilled to share our new paper, out today in @Nature: "Non-invasive profiling of the tumour microenvironment with spatial ecotypes". Paper (open access): nature.com/articles/s41586-0…

New @Nature study: >50% of lung cancer metastases are seeded by other metastases, not the primary tumor. This "seeding from seeding" reveals a complex evolutionary cascade that allows cancer to colonize the body. nature.com/articles/s41586-0…

Excited to share our latest @TrendsCancer @CellPressNews piece! DNA #methylation is a key predictor of how patients respond to #cancer treatments, including #immunotherapy and targeted therapies. #Epigenetics is becoming central to precision oncology! sciencedirect.com/science/ar…

Meet Trends Open: a new multidisciplinary, open-access reviews journal for commentaries and fresh perspectives across life, physical, health, sustainability, and applied sciences—welcoming early-career and established researchers. cell.com/trends-open/home

From our @Nature paper, where we demonstrate profound molecular heterogeneity even between two synchronous liver metastases. This is the challenge of advanced #PancreaticCancer. Targeting truncal mutations like KRAS overcomes some of this recalcitrance. nature.com/articles/s41586-0…

With news of @KeloniaTx's acquisition by $LLY yesterday, a fitting time to share our Review on in vivo CAR-T engineering, out now in @trendscancer! We summarize state-of-the-art approaches to in vivo engineering and open questions still ahead. Full text link in comments!